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Host antibacterial responses include mechanisms
that kill bacteria, but also those that protect or
tolerize the host to potentially damaging antibacterial
effects. We determined that Chitinase 3-like-1
(Chi3l1), a conserved prototypic chitinase-like pro-
tein, is induced by Streptococcus pneumoniae and
plays central roles in promoting bacterial clearance
and mediating host tolerance. S. pneumoniae-
infected Chi3l1 null mice exhibit exaggerated lung
injury, inflammation and hemorrhage, more frequent
bacterial dissemination, decreased bacterial clear-
ance, and enhanced mortality compared to controls.
Chi3l1 augments macrophage bacterial killing by
inhibiting caspase-1-dependent macrophage pyrop-
tosis and augments host tolerance by controlling
inflammasome activation, ATP accumulation, ex-
pression of ATP receptor P2X7R, and production of
thymic stromal lymphopoietin and type 1, type 2,
and type 17 cytokines. These data demonstrate
that Chi3l1 is induced during infection, where it
promotes bacterial clearance while simultaneously
augmenting host tolerance, and that these roles
likely contributed to the retention of Chi3l1 over
species and evolutionary time.
INTRODUCTION
The immune system has evolved to allow a host to control and
eliminate pathogens. It has long been assumed that the majority
of a host’s antipathogen defense strategy involves ‘‘resistance’’
mechanisms that attack the pathogen to block invasion and kill
and eliminate the offending organism (Schneider and Ayres,
2008). However, there is mounting evidence that the antipatho-
gen response can also cause critical and even fatal tissue injury.
This is particularly problematic in dysregulated and/or exagger-
ated innate immune responses, which because of their non-
specific nature are well known to induce immunopathology
(Gonc¸alves et al., 2001; Heimesaat et al., 2006; Peiris et al.,34 Cell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc.2010; Snelgrove et al., 2011). In keeping with this concept, there
is an evolving appreciation that the host can also respond to
pathogens with responses that limit this host-induced bystander
damage (Gatton and Cheng, 2002; Ma et al., 1998; Schneider
and Ayres, 2008; Sinton, 1938). The mechanisms that regulate
the self-harm that can be caused by a host antipathogen immune
response have been referred to asmechanisms of host tolerance
(different than immune tolerance), and the sum of a host’s resis-
tance and host tolerance can be thought of as a host’s defensive
capacity (Gatton and Cheng, 2002; Ma et al., 1998; Schneider
and Ayres, 2008). Although a great deal is known about the
molecular mechanisms that are used to kill and clear pathogens,
a systematic understanding of how a host regulates the produc-
tion, repair, and avoidance of the tissue damage that accumu-
lates during an infection is limited (Schneider and Ayres, 2008).
In particular, mechanisms that augment bacterial killing and
clearance while controlling innate immune response-induced
tissue injury have not been appropriately defined.
The glycosyl hydrolase 18 proteins (GH18) are members of an
ancient gene family and exist in species as diverse as plants,
insects, and man (Aerts et al., 2008; Funkhouser and Aronson,
2007). This gene family contains true chitinases (Cs), which
degrade chitin polysaccharides and chitinase-like proteins
(CLPs), which bind to but do not degrade chitin. Interestingly,
these GH18 moieties have evolved during speciation, with a
particularly impressive increase in CLP coinciding with the ap-
pearance of mammals (Funkhouser and Aronson, 2007). This
retention over species and evolutionary time has led to the belief
that these moieties play an essential role(s) in biology. However,
the role(s) that have allowed for this conservation and evolution
have not beendefined, and the biology of CLPs in normal homeo-
stasis and disease pathogenesis is poorly understood.
Chitinase 3-like-1 (Chi3l1, also called breast regression pro-
tein 39 [BRP-39] in the mouse and YKL-40 in man) is the proto-
typic mammalian CLP. It is expressed by a variety of cells,
including macrophages, neutrophils, and epithelial cells in the
lung and digestive tract (Homer et al., 2006; Lee and Elias,
2010; Mizoguchi, 2006). It is also highly regulated, being stimu-
lated by a number of mediators including IL-13 and IFN-g and
being detected in exaggerated quantities in the circulation and
or biologic fluids from patients with a spectrum of diseases
including asthma, COPD, rheumatoid arthritis, cancer, diabetes,
and atherosclerosis (Chupp et al., 2007; Lee et al., 2011;
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patients with community-acquired pneumonia requiring hospi-
talizations (Nordenbaek et al., 1999), patients with cystic fibrosis
and acute lung infections (Aris et al., 2000), and control subjects
following endotoxin injection (Johansen et al., 2005). Elevated
levels of Chi3l1 are especially prominent in patients with Strepto-
coccus pneumoniae (Sp) infections where they correlate posi-
tively with mortality (Kronborg et al., 2002; Østergaard et al.,
2002). In combination these studies suggest that elevated levels
of Chi3l1 can be an indicator of and a diagnostic and prognostic
marker of specific bacterial infections (Coffman, 2008). However,
the role(s) of Chi3l1 in the pathogenesis of antipathogen
responses have not been defined.
We hypothesized that Chi3l1 has been retained over species
and time because it plays a major role in antimicrobial re-
sponses. Specifically, we hypothesized that Chi3l1 augments
bacterial resistance and contributes to the ability of the host to
tolerate antibacterial responses. To test this hypothesis, we
evaluated the responses that were induced by Sp, the most
common cause of acute bacterial pneumonia in the USA (Lynch
and Zhanel, 2009), in wild-type (WT) and Chi3l1/ mice. These
studies demonstrate that Chi3l1 plays a critical role in anti-Sp
responses, with Chi3l1 null mice manifesting exaggerated lung
injury, inflammation, and hemorrhage, more frequent systemic
bacterial dissemination, decreased bacterial clearance, and
enhancedmortality compared toWT controls. They also demon-
strate that these effects are due to the ability of Chi3l1 to (1)
increase bacterial resistance by augmenting macrophage
bacterial killing while inhibiting a caspases-1-dependent pyrop-
tosis-like macrophage cell death response and (2) augment host
tolerance by controlling Sp-induced inflammasome activation
and regulating type 1, type 2, and type 17 immune responses.
RESULTS
S. pneumoniae Stimulates Chi3l1
To determine if Chi3l1 is regulated during bacterial infection, we
established a mouse pneumonia model using intratracheal Sp.
Uninfected wild-type (WT) C57BL/6 and heterozygous Chi3l1+/
mice had baseline levels of bronchoalveolar lavage (BAL) and
serumChi3l1 in the 50 ng/ml range (Figures 1A and 1B). Infection
of WTmice markedly increased the levels of Chi3l1 with levels of
BAL and serum Chi3l1 in the 3–4 mg/ml range and 150 ng/ml
range, respectively (Figures 1A and 1B). Immunohistochemistry
(IHC) demonstrated the enhanced Chi3l1 accumulation in airway
epithelial cells and recruited airway inflammatory cells (macro-
phages and neutrophils) in the lungs of infectedmice (Figure 1C).
Double labeling IHC demonstrated that this induction was prom-
inent in CD68+macrophages and CC10+ airway epithelial cells in
infected lungs (Figures 1D and 1E). This induction was not
specific for alveolar macrophages because Sp also stimulated
peritoneal macrophage production of Chi3l1 in a dose- and
time-dependent manner (Figures 1F and 1G). Thus, Chi3l1 is
prominently induced after Sp infection.
Chi3l1 Is a Critical Regulator of Acute Pneumococcal
Pneumonia
WT and Chi3l1/mice were inoculated with 53 105 cfu Sp, and
animals were monitored over time. Compared to infected WTCmice, infected Chi3l1/ mice manifest enhanced toxicity with
significantly greater body weight loss and augmented mortality
(Figures 2A and 2B). As regards to the latter, 50% of the null
mutant and WT mice expired approximately 4 and 8 days after
infection, respectively (Figure 2B). Similarly, 100% of the
infected Chi3l1/ mice died within 8 days of bacterial inocula-
tion compared to 60% peak mortality in infected WT controls
(Figure 2B). The enhanced sensitivity of null mutant mice was
associated with exaggerated lung injury manifested by
augmented neutrophil- and macrophage-rich BAL and tissue
inflammation (Figure S1), increased levels of hemorrhage (tissue
and BAL red blood cells), increased BAL protein accumulation,
and increased levels of CD11b+Gr-1+ neutrophils and myeloper-
oxidase (Figures 2C–2I). Importantly, the enhanced sensitivity of
Chi3l1 null mice could be ameliorated with recombinant (r)
Chi3l1. This can be seen in Figures 3A and 3B, which demon-
strate that the addition of rChi3l1 to our bacterial inoculum
decreased the weight loss and mortality of null mutant but not
WT animals. This was not due to a direct antibacterial effect of
Chi3l1 because incubation of Sp and rChi3l1 (from 16 ng/ml to
10 mg/ml) in vitro did not alter the titers of Sp bacteria in our infec-
tious inoculum (Figure 3C). These studies demonstrate that
Chi3l1 is a critical regulator of the severity of acute pneumo-
coccal pneumonia and its morbid consequences. They also
demonstrate that rChi3l1 can rescue the exaggerated sensitivity
of Chi3l1/ mice to Sp infection.
Chi3l1 Regulates Bacterial Clearance
and Dissemination
To begin to define the mechanism(s) by which Chi3l1 regulates
pneumococcal infection, WT and Chi3l1/ mice were infected
with Sp, and pulmonary bacterial titers and bacterial dissemina-
tion were evaluated 1 and 4 days later. At day 1, Chi3l1/ mice
displayed increased pulmonary bacterial loads compared to WT
animals (Figure 3D). These differences were even more promi-
nent 4 days postinfection, where the Chi3l1/ infected mice
exhibited approximately 1003 greater BAL and lung bacterial
burdens compared to infected WT controls (Figures 3D and
3E). In addition, 20% of the WT infected mice displayed posi-
tive Sp spleen cultures. In contrast, >70% of the comparably
infected Chi3l1/ mice had detectable splenic bacteria (Fig-
ure 3F). In accord with the findings noted above, Chi3l1/
mice that received Sp in the presence of rChi3l1 protein ex-
hibited decreased pulmonary bacterial burdens after infection
compared to Chi3l1/ mice that received bacteria alone (Fig-
ure 3G). These studies demonstrate that null mutations of
Chi3l1 are associated with decreased Sp clearance and
enhanced systemic Sp dissemination. They also demonstrate
that the defective clearance of bacteria in Chi3l1/ mice can
be rescued with rChi3l1 protein.
Chi3l1 Does Not Alter Bacterial Phagocytosis
Because Chi3l1/micemanifest a defect in bacterial clearance,
and Chi3l1 did not manifest direct bactericidal activity, studies
were undertaken to determine if Chi3l1 plays a role in bacterial
phagocytosis. First, we used peritoneal macrophages harvested
fromWT and Chi3l1/mice, incubated for 1 hr with flourescein-
labeled Sp in vitro, and analyzed using flow cytometry and Amnis
evaluations. Second, macrophages from WT and null mice wereell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc. 35
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Figure 1. Chi3l1 Is Induced During Streptococcus pneumoniae Infection
(A–C)WT, Chi3l1+/, and Chi3l1/mice were infected with 105 cfu/mouse of Sp intratracheally or control (). The levels of Chi3l1 protein were analyzed by ELISA
in the bronchoalveolar lavage fluid (BAL) (A) and serum (B). Immunohistochemistry was used to localize Chi3l1 (C, closed arrows depict macrophages and open
arrows, airway epithelial cells).
(D and E) Double-label immunohistochemistry with cell-specific antibodies (CD68, macrophages; CC10, airway epithelial cells). These are representative
composites of five similar evaluations. Arrows depict double-labeled cells.
(F) Peritoneal macrophages were infected with Sp at 2.5 3 104 cfu/well and incubated for 0, 1, 6, or 12 hr. Chi3l1 was evaluated by ELISA.
(G) Peritoneal macrophages were infected with 0, 104, 2.53 104, or 105 cfu/well of bacteria, supernatants were collected 6 hr later, and Chi3l1 was measured by
ELISA. The values in (A), (B), (F), and (G) are the mean (±SEM) of evaluations of a minimum of eight mice and are representative of three experiments. Scale bar,
50 mm. n.d., none detected. *p < 0.05, **p < 0.01, ***p < 0.001.
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Chi3l1 Regulation of Pneumococcal Lung Infectionincubated in vitro with unlabeled bacteria for 1 hr, washed, and
incubated with antibiotic for an additional hour before cells
were lysed and bacterial titers assessed by plating on blood
agar. In the former experiments using labeled bacteria, similar
levels of labeled Sp were seen in macrophages from WT and
Chi3l1/ mice (Figure 3H). Importantly, the Amnis evaluations
demonstrated that the Sp was intracellular and not adherent to
the surface of themacrophages (Figure S2). Similarly, in the latter
experiments studying lysed infected cells, similar numbers of Sp
were seen in the cells from the infected and antibiotic-treated
macrophages (Figure 3I). Thus, these studies demonstrate that
the Chi3l1/ and WT macrophages exhibited similar abilities
to ingest Sp.
Chi3l1 Regulates Bacterial Killing
To assess macrophage bacterial killing, macrophages from WT
and null mice were incubated with unlabeled bacteria for 6 hr36 Cell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc.in vitro, washed, and lysed, and bacterial titers were assessed
after plating on blood agar. Chi3l1/ macrophages contained
higher titers of bacteria than cells from WT controls, demon-
strating that the null cells have a defect in intracellular bacterial
killing (Figure 3J). Importantly, addition of rChi3l1 protein to our
bacterial aliquots rescued the bacterial killing response in
Chi3l1/ macrophages (Figure 3K). These studies demonstrate
that Chi3l1 plays a critical role in intracellular Sp killing.
Chi3l1 Regulates a Caspase-1-Dependent Macrophage
Cell Death Response
We demonstrated previously that Chi3l1 is an important inhibitor
of macrophage apoptosis (Lee et al., 2009). Thus, studies were
undertaken to determine if the impaired bacterial killing in
Chi3l1/macrophages was due to an exaggerated Sp-induced
cell death response. In these experiments, macrophages from
WT and null mice were incubated with varying doses of Sp
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Figure 2. Chi3l1 Plays a Critical Role in the Control of Acute Pneumococcal Infection and Regulates Lung Inflammation and Injury
(A and B) WT or Chi3l1/mice were infected intratracheally with Sp, and body weight (expressed as% original body weight) (A) andmortality (B) were assessed.
(C–I) WT or Chi3l1/mice were infected intratracheally with Sp. Total BAL cell recovery and differential cell recoveries were assessed (C). Tissue histology (H&E
stain) (D), RBC recovery (E), BAL protein (F), and the percentage and numbers of CD11b+Gr-1+ cells (G and H) were assessed via FACS analysis of single lung cell
suspensions, as well as the levels of lung lysatemyeloperoxidase (MPO) (I). Unless otherwise noted the datawere obtained 4 days after infection. The values in (A),
(C), (E), (F), (H), and (I) represent the mean (±SEM) of evaluations in a minimum of five animals and are representative of three experiments. NS, not significant.
Scale bar, 100 mm. *p < 0.05, **p < 0.01. (See also Figure S1.)
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Chi3l1 Regulation of Pneumococcal Lung Infection(moi 0, 1, 5, 20), and apoptosis was assessed using TUNEL
staining and Annexin V evaluations by flow cytometry (Figure 4A).
At baseline, the levels of TUNEL staining and Annexin V expres-
sion were higher in null versus WT cells. However, these differ-
ences did not achieve statistical significance (Figure 4A, white
open bar). In contrast, after infection with all dosages of bacteria,
the levels of TUNEL staining and Annexin V expression were
significantly higher in null versus WT cells (Figures 4A and 4B).
The levels of LDH release were also higher in null versusWT cells
after infection (Figure 4C). In all cases, the addition of rChi3l1
protein to the Sp aliquots rescued these bacterially induced
exaggerated cell death responses in Chi3l1/ cells (Figures
4C, 4D, and S3). These studies demonstrate that Chi3l1 is a
critical regulator of macrophage survival.
To further understand the exaggerated cell death response in
infected Chi3l1 null macrophages, we assessed the regulationCand role(s) of caspase-1 in these responses. These studies
demonstrated that the levels of caspase-1 activity were higher
in infected peritoneal macrophages from null versus WT mice
in vitro (Figure 4E). In accord with this finding, the caspase-1
activity in isolated macrophages from infected lungs of Chi3l1
null micewas greater thanWT controls (Figure 4F). These studies
also demonstrated that the increased induction of Annexin
V+ cell death was abrogated by the specific caspase-1 inhibitor
YVAD-CHO compared to its DMSO vehicle control (Figure 4G).
Accordingly, the levels of Annexin V+ staining after bacterial
infection were diminished in Chi3l1/ 3 caspase-1/ double
knockout macrophages compared to comparably treated cells
from Chi3l1/ mice (Figure 4H). When viewed in combination,
these studies demonstrate that Chi3l1 is an important inhibitor
of a Sp-induced, caspase-1-dependent, macrophage pyropto-
sis-like cell death response.ell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc. 37
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Figure 3. Effects of Recombinant Chi3l1
(A and B) WT and Chi3l1/ mice were infected intratracheally with S. pneumoniae (Sp) or with Sp incubated with 10 mg/ml of rChi3l1. Daily weights of infected
mice were recorded (A). Survival of WT or Chi3l1/mice infected with Sp or with Sp incubated with rChi3l1 was assessed (B). Black boxes, WTmice + Sp; white
boxes, WT mice + Sp+rChi3l1; black triangles, Chi3l1/ mice + Sp; white triangles, Chi3l1/ mice + Sp+rChi3l1.
(C) Spwas incubated for 16 hr in the presence and absence of 5-fold dilutions of rChi3l1 (from 10 mg/ml to 16 ng/ml), doxycycline (1 mg/ml), or media control, and
bacterial growth was assessed.
(D–F) WT and Chi3l1/ mice were infected intratracheally with 5 3 105 cfu/mouse Sp. Lungs from infected WT and Chi3l1/ mice were harvested 1 or 4 days
postinfection, and tissue bacterial counts were determined (D). BAL from infected WT and Chi3l1/ mice were prepared 4 days after inoculation, and bacterial
counts were determined (E). Spleen lysates from WT and Chi3l1/ mice were prepared 4 days after bacterial inoculation, and the percentage of mice with
positive spleen cultures was assessed (F).
(G) WT and Chi3l1/mice were infected with 105 cfu Sp in the presence or absence of 10 mg/ml rChi3l1. One day later, lung lysate recovered bacterial load was
determined by plating on blood agar.
(H) Peritoneal macrophages from WT or Chi3l1/mice were treated for 60 min with 10:1 and 2.5:1 ratios of fluorescein-labeled Sp to cells. Cells were gated on
macrophages according to forward and side scatter properties. Average fluorescein units are shown for WT or Chi3l1/ cells (n = 5).
(I) Peritoneal macrophages fromWT or Chi3l1/mice were treated with a 10:1 ratio of unlabeled Sp to cells in media first without antibiotics for 60 min, followed
by media with antibiotics for 60 min. The cells were then washed and lysed, and phagocytosed bacteria were quantitated (n = 4).
(J) Peritoneal macrophages fromWT or Chi3l1/mice were treated with 10:1 ratio of unlabeled Sp to cells in media without antibiotics for 60min, then incubated
with gentamicin to kill extracellular bacteria, and viable bacteria were assessed 6 hr later (n = 4).
(K) Peritoneal macrophages from WT or Chi3l1/mice were treated with Sp in the absence or presence of rChi3l1, and at 6 hr, viable intracellular bacteria were
assessed. The values in this figure represent the mean (±SEM) of evaluations in a minimum of five animals and are representative of three experiments. NS, not
significant. *p < 0.05, **p < 0.01. (See also Figure S2.)
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Chi3l1 Regulation of Pneumococcal Lung InfectionChi3l1 Regulates Inflammasome Activation and the
Purinergic Pathway In Vivo
Because the studies noted above demonstrate that caspase-1 is
activated in cells from Chi3l1 null mice, studies were undertaken38 Cell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc.to determine if Chi3l1 regulates the production of caspase-1/
inflammasome-dependent cytokines such as IL-1b and IL-18.
As can be seen in Figures 5A and 5B, the levels of these cyto-
kines in BAL from infected null mice was significantly greater
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Figure 4. Chi3l1 Regulates Macrophage Cell Death
(A) Peritoneal macrophages from WT or Chi3l1/ mice were incubated with 0, 104, 2.5 3 104, and 105 cfu Sp/well for 12 hr. Cells were fixed and TUNEL stains
were performed.
(B) Infected peritoneal macrophages were harvested and stained with Annexin V-FITC, and the percentage of cells that expressed Annexin V was determined.
(C) Macrophages from WT or Chi3l1/ mice treated with Sp in the absence or presence of rChi3l1 and LDH release were assessed. The values are expressed
as the percentage of the LDH released by similar numbers of cells treated with Triton-X.
(D)Macrophages fromWT or Chi3l1/mice were treatedwithSp in the presence or absence of rChi3l1, and the percentage of cells expressing Annexin V by flow
cytometry was assessed.
(E) Peritoneal macrophages from WT or Chi3l1/ mice were treated with Sp in the presence or absence of rChi3l1, and lysate caspase-1 bioactivity was
measured using a colorimetric assay.
(F) CD45+ adherent cells from infected WT or Chi3l1/ lungs were measured for their caspase-1 bioactivity.
(G) Annexin V staining by flow cytometry of macrophages (WT or Chi3l1/) infected with Sp in the presence of DMSO (vehicle control) or YVAD-CHO caspase-1
inhibitor.
(H) Annexin V staining by flow cytometry of macrophages from WT, Chi3l1/, Chi3l1/ 3 Caspase-1/, or Caspase-1/ mice infected with Sp. The
data shown in (A)–(H) represent the mean ± SEM of a minimum of five mice in each assessment. NS, not significant. *p < 0.05. (See also Figure S3.)
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Chi3l1 Regulation of Pneumococcal Lung Infectionthan in BAL from similarly challenged WT mice. These findings
were at least partially specific for these moieties because the
levels of other proinflammatory cytokines (TNF-a and IL-6)
were not similarly altered (Figures 5C and S4). We also found
that Sp-stimulated IL-33 secretion was increased in Chi3l1/
mice versus wild-type controls. However, this cytokine responseCwas not caspase-1 inflammasome dependent, as demonstrated
in studies comparing Chi3l1/ and Chi3l1/caspase-1 double
null animals (Figure S4). In keeping with the concept that inflam-
masome activity is enhanced in Chi3l1/ mice, comparisons
of lysates, BAL, and mRNA from lungs from infected null and
WT mice demonstrated that the null mice manifest enhancedell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc. 39
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Figure 5. Chi3l1 Regulates Inflammasome Activation and the Purinergic Pathway
(A–C) WT and Chi3l1/mice were infected intratracheally with Sp, and BAL fluid IL-1b (A) and IL-18 (B) were assessed 1 or 4 days after inoculation. The levels of
BAL TNF and IL-6 were assessed 4 days after inoculation (C). BAL fluids of mock infected animals were obtained at day 4.
(D–G)WT andChi3l1/micewere infectedwithSp and 1 or 4 days later the levels ofmRNA encodingNlrp3 (D) and ASC (E) in isolated lung lysates were assessed
by real-time RT-PCR. Similarly, isolated macrophages from WT and Chi3l1/ mice were infected in vitro with Sp and measured for Nlpr3 (F) and ASC (G)
expression.
(H) WT and Chi3l1/ mice were infected with Sp, and the levels of BAL ATP were assessed 4 days later.
(I and J) WT and Chi3l1/mice were infected with Sp, and the levels of mRNA encoding the purinergic receptors P2X7R (I) and P2X4R (J) were assessed using
real-time RT-PCR. Expression is normalized to a b-actin control and presented as the fold increase compared to mock treated WT mice. Error bars represent
mean ± SEM. NS, not significant. *p < 0.05, **p < 0.01. (See also Figure S4.)
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Chi3l1 Regulation of Pneumococcal Lung Infectionlevels of themature form of IL-1b and enhanced levels of expres-
sion of Nlrp3 and the inflammasome adaptor Asc in the lungs
(Figures 5D and 5E) and macrophages (Figures 5F and 5G).
Because it is known that extracellular ATP, which is often
increased in settings characterized by cellular damage, can act
as a cofactor in inflammasome activation, the levels of ATP
and ATP receptors were also evaluated. These studies demon-
strate that bacteria-infected Chi3l1/ mice have significantly
higher levels of measurable BAL ATP (Figure 5H), as well as
increased levels of the P2x7r ATP receptor compared to WT
controls (Figure 5I). The P2x4r was not similarly regulated (Fig-
ure 5J). Importantly, these alterations played a significant role
in the exaggerated Sp-induced responses in Chi3l1/ mice,
because BAL inflammation and IL-1b production were40 Cell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc.decreased in Chi3l1/ infected mice treated with siRNA against
P2X7R (Figures 6A, 6B, and S6). When viewed in combination,
these studies demonstrate that the inflammasome, inflamma-
some activity, and the production of inflammasome-dependent
cytokines are increased after Sp infection in the absence of
Chi3l1. They also demonstrate that ATP accumulation and
P2X7R expression are exaggerated in this setting and play an
important role(s) in this response.
The Chi3l1-Regulated Inflammasome Utilizes
Caspase-1 and Nlrp3
To further understand the interaction of Chi3l1 and the inflamma-
some, in vitro approaches were employed. These studies
demonstrate that macrophages from Chi3l1/ mice, when
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Figure 6. Chi3l1 Regulates an Inflammasome that Utilizes Caspase-1 and Nlpr3
(A and B) BAL cell numbers (A) and IL-1b levels in BAL (B) in Sp-infected WT mice, Chi3l1/ mice, and mice treated with scrambled siRNA, Nlrp3 siRNA, and
P2X7R siRNA.
(C) Peritoneal macrophages fromWT or Chi3l1/mice were infected with Sp at 10:1 bacteria to cell ratio, and supernatant IL-1b was assessed by ELISA at the
noted intervals thereafter.
(D) Macrophages fromWT or Chi3l1/mice were treated with Sp as indicated for 16 hr, and lysates and supernatant (SN) IL-1bwere assessed via western blot
analysis. Pro-IL-1b and the mature form of IL-1b are indicated. A control immunoblot using antibodies against b-tubulin is included.
(E and F) Peritoneal macrophages fromWT or Chi3l1/mice were treated with LPS for 12 hr followed by ATP (5 mM) for 30 min. The levels of supernatant IL-1b
were assessed by ELISA (E), and supernatant and lysate IL-1b protein were assessed by immunoblot (F).
(G) Macrophages from WT or Chi3l1/ mice treated with or without Sp, and 16 hr later caspase-1 was assessed via western blot analysis. Pro-caspase-1 and
cleaved caspase-1 (p10) are shown. Control immunoblot using antibodies against b-tubulin is included.
(H) Macrophages from WT mice, Chi3l1/ mice, caspase-1/ mice, and Chi3l1/ 3 Caspase-1/ mice were infected with Sp, and supernatant IL-1b was
assessed by ELISA 16 hr later.
(I) Macrophages from WT mice, Chi3l1/ mice, Nlrp3/ mice, and Chi3l1/ 3 Nlrp3/ mice were infected with Sp, and supernatant IL-1b was assessed
by ELISA 16 hr later.
(J) BAL IL-1b levels in infectedWT, Chi3l1/mice, and Chi3l1/3Caspase-1/mice. Error bars represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (See
also Figure S5.)
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Chi3l1 Regulation of Pneumococcal Lung Infectioninfected with Sp, exhibited an exaggerated time- and dose-
dependent increase in IL-1b production compared to macro-
phages from infected WT mice (Figure 6C and data not shown).
Increased levels of pro-IL-1b andmature IL-1b in cell lysates and
increased secretion of mature IL-1b into cell supernatants were
also observed in comparisons of infected WT and Chi3l1/
macrophage cultures (Figure 6D). These effects were not Sp
specific because similar results were seen when other inflamma-
some activators were employed. Specifically, we noted thatCChi3l1/ macrophages produced more mature IL1-b than cells
fromWTmicewhen treatedwith the prototypic activating combi-
nation of LPS plus ATP (Figures 6E and 6F). We also noted that
Sp-infected Chi3l1/ macrophages contained increased levels
of activated (cleaved) caspase-1 compared to similarly infected
WT cells (Figure 6G). Importantly, macrophage production of
mature IL-1b after Sp infection was dependent on Nlrp3 and cas-
pase-1 because the production of this cytokine was significantly
diminished in WT macrophages and Chi3l1 null macrophagesell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc. 41
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Figure 7. Chi3l1 Regulation of Cytokine Production In Vivo
(A–D)WT and Chi3l1/micewere infected with or without Sp. BALwas undertaken 4 days later, and Th1 cytokines (IL-12p70 and interferon-g) (A), Th2 cytokines
(IL-13, IL-4, and IL-5) (B), TSLP (C), and IL-17 (D) were measured using ELISA. The values in (A)–(D) represent the mean (±SEM) of evaluations in a minimum of
eight animals and are representative of two experiments. NS, not significant. Scale bar, 100 um. *p < 0.05, **p < 0.01. (See also Figure S6.)
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Chi3l1 Regulation of Pneumococcal Lung Infectionthat lacked Nlrp3 or caspase-1 (Figures 6H and 6I). Moreover,
BAL inflammation and IL-1b production were decreased in
Chi3l1/ infected mice treated with siRNA against Nlrp3
(Figures 6A, 6B, and S5) and Chi3l1/ infected mice that were
also deficient in caspase-1 (Figure 6J). When viewed in combina-
tion, these studies demonstrate that Chi3l1 is an important
inhibitor of the activation of an Nlrp3 inflammasome in vivo and
in vitro.
Chi3l1 Regulation of Cytokine Profile In Vivo
Studies were next undertaken in vivo to determine if the
presence or absence of Chi3l1 altered the spectrum and quanti-
ties of cytokines that were induced by Sp. As shown in Figure 7,
Sp infection caused a significant increase in the prototypic type 1
cytokines IL-12 and IFN-g and decreases in the classic type 2
cytokines IL-13, IL-4, and IL-5, the T helper 2 (Th2) augmenting42 Cell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc.cytokine thymic stromal lymphopoietin (TSLP), and the
prototypic type 17 cytokine IL-17A. When compared to WT
mice, Chi3l1 null mice produced significantly greater levels of
IL-12, IFN-g, and IL-23p19 (Figures 7A and S6). In contrast,
these mice manifest impressively decreased levels of IL-13,
IL-4, IL-5, TSLP, and IL-17A (Figures 7B–7D). Thus, Chi3l1 plays
a major role in the regulation of Sp-induced cytokine responses,
where it augments the production of type 2 cytokines, type 17
cytokines, and TSLP while decreasing type 1 cytokine
responses.
DISCUSSION
To further our understanding of the biology of CLPs, we tested
the hypothesis that CLPs play an essential role in antibacterial
responses. To test this hypothesis, we evaluated the
Cell Host & Microbe
Chi3l1 Regulation of Pneumococcal Lung Infectionantimicrobial responses in WT and Chi3l1/ mice infected with
Sp. These studies demonstrate that Sp is a powerful stimulator
of macrophage and epithelial Chi3l1 production and that null
mutations of Chi3l1 result in exaggerated lung hemorrhage,
injury and inflammation, systemic bacterial dissemination, and
diminished survival after infection. They also demonstrate that
these alterations are associated with a defect in pulmonary
bacterial clearance and macrophage bacterial killing. Lastly,
they highlight mechanisms that underlie these responses by
demonstrating that Chi3l1 augments macrophage bacterial
killing by inhibiting macrophage pyroptosis and controls inflam-
mation and injury by inhibiting Sp-induced Nlrp3 inflammasome
activation, ATP accumulation, and P2X7R expression and regu-
lating type 1, type 2, type 17 cytokine, and TSLP elaboration.
These studies demonstrate that Chi3l1 is a critical regulator of
antibacterial responses that augments antimicrobial resistance
by contributing to bacterial killing and controlling bacterial
dissemination. They also demonstrate that Chi3l1 is a critical
regulator of host tolerance that inhibits inflammasome and puri-
nergic activation and regulates cytokine balance. When viewed
in combination, they suggest that the stimulation of Chi3l1 that
is seen during bacterial infections augments bacterial clearance
and feeds back to diminish bystander immunopathology. They
also raise the possibility that these essential antibacterial roles
have contributed to the retention of Chi3l1 over species and
evolutionary time.
S. pneumoniae has been described as an ‘‘extracellular’’ path-
ogen, which is generally considered to be killed by phagocytic
ingestion, which can be facilitated by opsonic antibodies (Lu
et al., 2008). Our studies provide insights into the complexities
that underlie this response. Specifically, they demonstrate that
Chi3l1 null mice manifest exaggerated injury and inflammation
and enhanced mortality compared with WT controls after
Sp infection. They also demonstrate that these responses are
associated with increased bacterial titers and that macrophages
from Chi3l1/ mice ingest Sp but fail to kill it in an appropriate
manner. This microbicidal failure was associated with
augmented macrophage cell death, and this cell death response
was associated with caspase-1 activation and mediated by
a caspase-1-dependent mechanism. These studies demon-
strate that Sp induces macrophage pyroptosis and that Chi3l1
inhibits this cell death response. In accord with the proinflamma-
tory nature of macrophage pyroptosis (Kepp et al., 2010;
Khare et al., 2010), our studies demonstrate that Sp-induced
pyroptosis is seen in the context of intense inflammation and
the exaggerated production of IL-1b and IL-18, which are
caspase-1-dependent cytokines (Kepp et al., 2010; Miggin
et al., 2007). There is, however, one aspect of our findings and
prior reports that deserves additional comment. Specifically, in
its present conceptualization, pyroptosis is believed to be anti-
bacterial where it counters bacterial replication and clears
infected cells (Lamkanfi and Dixit, 2011). In contrast, our studies
demonstrate that in the absence of Chi3l1, pyroptosis decreases
Sp killing. These studies demonstrate that pyroptosis must be
appropriately regulated to confer its antibacterial effects. In
combination, these observations suggest that pyroptosis, like
inflammasome activation, can have protective effects or
contribute to disease pathogenesis (Bortoluci and Medzhitov,
2010). In accord with this concept, although a variety of patho-Cgens including Listeria monocytogenes, Staphylococcus aureus,
andCandida albicans activate caspase-1 via an Nlrp3 inflamma-
some, direct evidence that Nlrp3-mediated pyroptosis contrib-
utes to the control of these pathogens is lacking (Bortoluci and
Medzhitov, 2010). In addition, in Plasmodium chabaudi infec-
tions, instead of parasite control, inflammation induced by
Nlrp3 is implicated in the development of pathology including
fever, weight loss, and mortality (Bortoluci and Medzhitov,
2010; Shio et al., 2009). At present it is not clear when pyroptosis
and caspase-1 activation are beneficial versus pathologic. It is
tempting, however, to speculate that these responses contribute
to bacterial clearance when appropriately regulated by mole-
cules such as Chi3l1 and contribute to disease pathogenesis
when dysregulated, as seen in the Chi3l1/ mice in this report.
S. pneumoniae is the leading cause of pneumonia causing
hospitalization and an important cause of meningitis and sepsis
(Lynch and Zhanel, 2009). In keeping with its importance, the
cellular and molecular events that are involved in antipneumo-
coccal responses have been extensively investigated. The
studies have highlighted a number of important events, including
NF-kB activation and the production of TNF, IL-1b, and IL-6
(Calbo and Garau, 2010; Paterson and Orihuela, 2010). They
have also highlighted the importance of a controlled immune
response, which clears the pathogen without inducing excess
tissue injury (Austrian and Gold, 1964; Calbo and Garau, 2010).
This includes studies that demonstrate that mice that lack the
p50 subunit of NF-kB (which inhibits the elaboration of proin-
flammatory cytokines) manifest enhanced inflammation and
death despite appropriate bacterial clearance, studies high-
lighting the importance of the anti-inflammatory cytokine IL-10
in antipneumococcal responses, and studies that demonstrate
that the exaggerated morbidity and mortality that is seen with
the simultaneous infection with influenza and Sp are the result
of dysregulated inflammation (Calbo and Garau, 2010; Paterson
and Mitchell, 2006). The studies of pneumococcal vaccine
responses have also highlighted the importance of appropriately
balanced type 1, type 2, and type 17 immunity in these protective
responses (Ferreira et al., 2008; Littmann et al., 2011; Moffitt
et al., 2011; Schmid et al., 2011). Our studies add to these obser-
vations in a number of important ways. First, they demonstrate
that Sp is a potent inflammasome activator, augments the elab-
oration of ATP and the expression of the P2X7 ATP receptor, and
stimulates a mixed type 1, type 2, and type 17 responses and
TSLP elaboration. They also demonstrate that Chi3l1 plays an
important role in bacterial clearance and is an important regu-
lator of the appropriateness of anti-Sp responses and that it
does this by augmenting bacterial killing, controlling macro-
phage pyroptosis and inflammasome and purinergic activation,
and by regulating the profile of cytokine elaboration.
As noted above, our studies demonstrate that Chi3l1 is an
important regulator of the intensity of Sp-induced cytokine
responses. The demonstration that type 2 responses are dimin-
ished in infected mice that lack Chi3l1 is in accord with studies
from our laboratory that demonstrated that Chi3l1 plays a critical
role in aeroallergen-induced pulmonary inflammation (Lee et al.,
2009). The present studies add to our understanding of the
biology of Chi3l1 by demonstrating that Chi3l1 also inhibits type
1, type 17, and IL-1-b and IL-18 responses. Although the mech-
anisms that underlie these regulatory events have not beenell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc. 43
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Chi3l1 Regulation of Pneumococcal Lung Infectionfully elucidated, our data provide a number of insights. First, they
demonstrate that Chi3l1 regulates the production of inflamma-
some-dependent moieties (IL-1b and IL-18) and cytokines that
have not been associated with inflammasome activation (Th1,
Th2, and TSLP cytokines). Although IL-33 has been reported to
be produced by inflammasome-dependent and -independent
mechanisms (Schmitz et al., 2005; Zhao and Hu, 2010), our
studies highlight its caspase-1 inflammation-independent nature
in this setting. Importantly, our studies also provide insight into
mechanism(s) that may mediate the regulation of IL-17 in this
setting. IL-1b and IL-23 are both potent stimulators (Brereton
et al., 2009; Sutton et al., 2009) while type 1 immune responses
inhibit IL-17 production (Cobb and Smeltz, 2012; Durrant and
Metzger, 2010). Interestingly, in this experimental system, the
levels of IL-17 were decreased while the IL-1b, type 1 cytokine,
and IL-23 responses were increased. This demonstrates that
the inhibition of IL-17 in Chi3l1/ mice is mediated via an
IL-1b- and IL-23-independent mechanism. These findings also
allow for the interesting speculation that the inhibition ismediated
by the accompanying exaggerated type 1 cytokine response.
Additional investigation will be required to fully understand
each of these important regulatory events.
The immune system provides protection from a wide range of
pathogens. One component, the phylogenetically ancient innate
immune response, fights infection from the moment of contact
and is a fundamental weapon of multicellular organisms (Kim-
brell and Beutler, 2001). Innate immune activation, however,
can be a double-edged sword that contributes to tissue injury,
chronic inflammation, and autoimmunity when unchecked
(Liew et al., 2005; Sirisinha, 2011). Studies over recent years
have described the numerous negative regulators that control
innate immunity, including soluble receptors, transmembrane
immunoreceptor tyrosine-based inhibitory motif (ITIM) proteins,
and intracellular TLR regulators (Liew et al., 2005; Sirisinha,
2011). Our studies add to this understanding by demonstrating
that Chi3l1 is also a powerful inhibitor of innate immunity and
that it does this by controlling inflammasome activation, the
production of the damage-associated molecular pattern
(DAMP) ATP, and the expression of the P2X7 ATP receptor.
Recent studies demonstrated that interventions that prevent
cell death, decrease the phagocytosis of dying cells, and prevent
ATP release or regulate MAP kinase and/or AKT pathway
signaling can inhibit inflammasome activation (Ali et al., 2011;
Hu et al., 2010). Although the mechanism(s) by which Chi3l1
inhibits inflammasome activation are unknown, it is tempting to
speculate that one or more of these mechanisms are involved
because studies from our laboratory and others have demon-
strated that Chi3l1 inhibits apoptosis and pyroptosis and is
known to regulate MAPK and AKT activation (Lee et al., 2009,
2011; Lee and Elias, 2010). Our studies have also demonstrated
that Chi3l1 augments adaptive Th2 inflammation, TGF-b1 elabo-
ration, and the healing and repair process (Lee et al., 2009). In
combination these studies suggest that Chi3l1 is a key regulator
of antibacterial responses that augments bacterial killing, regu-
lates the appropriateness and intensity of antibacterial innate
immune responses, and facilitates the transition to adaptive
immunity while augmenting healing and repair. Additional inves-
tigation of the roles of Chi3l1 in bacterial clearance and immunity
and the utility of rChi3l1 in these infectious events is warranted.44 Cell Host & Microbe 12, 34–46, July 19, 2012 ª2012 Elsevier Inc.EXPERIMENTAL PROCEDURES
Animals
Chi3l1/ (or BRP-39/) mice on a C57BL/6 background have been gener-
ated and described by our laboratory (Lee et al., 2009). Caspase-1/ and
Nlrp3/ mice were obtained from Dr. Richard Flavell, Yale University. All
animal studies were approved by the Yale IACUC.
Bacteria
Ply+ S. pneumoniae type 3 was used in this study (ATCC #6303). It was stored
at80C in Todd-Hewitt Broth (THB) containing 10% glycerol. After overnight
incubation on 5% sheep blood agar plates (BD Biosciences), freshly grown
colonies were suspended in THB and incubated for 2 hr at 37C to logarithmic
growth, pelleted, and resuspended in PBS. Bacterial concentrations were as-
sessed by serial dilutions. Fluorescein-labeled bacteria were prepared as
described (Vander Top et al., 2006). Bacteria were incubated at 37C for
30 min with equal volume of 2.0 mM solution of 5- (and 6-) carboxyfluorescein
diacetate succinimidyl ester (CFDA/SE, Molecular Probes).
In Vivo and In Vitro Sp Infection Model
Under anesthesia (ketamine/xylazine), WT or Chi3l1/ mice were intratra-
cheally inoculated with 105 cfu of Sp or PBS. Infected mice were observed
for weights and survival data. Infected mice were sacrificed 1 and 4 days after
infection. Blood samples were collected. Single-cell suspensions of spleens
were prepared and plated on blood agar plates to determine the presence
of bacteria. Elicited peritoneal macrophages from WT and Chi3l1/ mice
were harvested 5 days after intraperitoneal inoculation of 10% thioglycollate
broth (Difco Laboratories) and infected with bacteria at various multiplicities
of infection (moi) as indicated or treated with LPS (Invivogen) and ATP
(Sigma).
BAL and Lung Inflammation
Lung inflammation was assessed by BAL as described previously (Kang et al.,
2007). Total RBCs, nucleated cell numbers, and differentials were assessed.
Cells were stained with Diff-Quik for cell differentiations. Cell-free BAL fluid
was used for cytokine measurements. Lungs were removed, inflated at
25 cm pressure with 0.5% low melting agarose, fixed and embedded in
paraffin, sectioned, and stained. H&E stain was performed in the Yale
Research Histology. BAL protein concentration was determined by BCA assay
(Pierce). Myeloperoxidase activity in lung homogenates was assayed using
3,30,5,50-tetramethylbenzidine (Sigma).
Quantitation of Chi3l1 and Cytokines
The concentrations of Chi3l1 in BALwere evaluated by ELISA using anti-Chi3l1
rabbit polyclonal IgG and detecting with biotinylated anti-Chi3l1 antibody
(MedImmune) and horseradish peroxidase-labeled streptavidin (Amersham).
Concentrations of cytokines were assessed using commercially available
ELISA Kits (R&D Systems and eBioscience) according to manufacturer’s
instructions.
mRNA Analysis
mRNAconcentrations were assessed using real-time RT-PCR as described by
our laboratory (Kang et al., 2008; Matsuura et al., 2011). The sequences for
the primers used in real-time RT-PCR experiments were obtained from
PrimerBank (http://pga.mgh.harvard.edu/primerbank).
Immunoblot Analysis
Precipitated media supernatants or cell extracts were analyzed by standard
immunoblot techniques. Primary antibodies used were polyclonal goat anti-
body to mouse-IL-1b (anti-mouse IL-1b; R&D Systems, Santa Cruz), poly-
clonal rabbit anti-caspase-1 (Santa Cruz), and polyclonal rabbit antibody to
b-tubulin (Cell Signaling). Fifty micrograms of supernatant fluids and/or cell
lysates were subjected to immunoblot analysis, fractionated by PAGE, and
transferred to membranes.
Immunohistochemistry, Immunofluorescence, and Amnis Imaging
Immunohistochemistry of Chi3l1 was performed as described (Lee et al., 2009;
Matsuura et al., 2011) using rabbit anti-Chi3l1 polyclonal antibody
Cell Host & Microbe
Chi3l1 Regulation of Pneumococcal Lung Infection(MedImmune). Double-labeled immunofluorescence was performed using
antibodies against CD68 (eBioscience) and CC10 (Santa Cruz) to identify
macrophages and airway epithelial cells. ToPro-3 was used to stain the
nucleus (Invitrogen). Fluorescent images were captured using the LEICA
DMIRB microscope. For Amnis experiments, peritoneal macrophages were
incubated with labeled bacteria (moi 25:1) and incubated for 2 hr at 37C in
serum-free media, followed by PBS washes prior to staining with anti-mouse
F4/80-PE (BD Biosciences), washes, and fixation with 1% formaldehyde.
Data was acquired on an Image Stream Multi-Spectral Flow Cytometer. At
least 50,000 cells were acquired.
FACS Analysis
Whole-lung cell suspensions were obtained by a previously described
method (Lee et al., 2009). Briefly, lung tissue was digested using dispase
(Stem Cell Technologies), collagenase (Sigma), and DNaseI (Sigma). Cells
were put through varying sizes of strainers (from 100 mm to 40 mm), and
were resuspended in PBS/2% FCS. Cells were incubated with purified
rat anti-mouse CD16/CD32 monoclonal antibody (1 mg/105 cells; BD
Biosciences) to prevent nonspecific binding to Fc receptors. Cells were
incubated for 30 min at 4C with specific antibodies for surface marker
staining for Gr-1 and CD11b to identify neutrophils. Surface markers
CD45 and F4/80 were used to identify lung macrophages. Markers
CD45, SiglecF, and CD11c were used to identify eosinophils. Cell popula-
tions were analyzed using FACSCalibur. At least 10,000 cells per sample
were analyzed.
Macrophage Apoptosis/Cell Death Evaluation
TUNEL-positive cells on paraffin-embedded tissue were identified using
terminal deoxynucleotidyl transferase dUTP nick-end labeling In Situ Cell
Death Detection Kit (Roche). Cell death was assessed using Annexin V staining
(BD Biosciences) as previously described by our laboratory (Lee et al., 2009).
LDH release was assayed using the Cytotoxicity Detection Kit as described by
the manufacturer’s protocol (Roche). Ten percent Triton-X-treated cells serve
as 100% for LDH release.
Silencing RNA
Nlrp3 and P2X7R siRNAs were synthesized that were deprotected, desalted,
and BioRPTM purified (Bioneer). For each of the gene targets, we used
three pooled siRNA sequences. See Supplemental Information for siRNA
sequences used for Nlrp3 and P2x7r. Nlrp3, P2x7r, and irrelevant (scrambled
control) siRNAs were delivered intranasally. We used 60 mg dose of siRNA per
mouse given 12 hr prior to Sp infection. Lung tissues were collected 24 hr after
infection.
Statistical Analysis
Statistical evaluations were undertaken with GraphPad Prism software.
Normally distributed data are expressed as mean ± SEM and were assessed
for significance using a Student’s t test or ANOVA as appropriate. Data that
were not normally distributed were assessed for significance using the Krus-
kal-Wallis test, followed by the Mann-Whitney U test to compare individual
groups. Statistical significance was defined as a p value less than 0.05.
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